The leading cause of death for U.S. citizens is cardiovascular disease, which affects nearly a third of the U.S. population. There is an active and dedicated search for effective therapies to address this serious medical issue. The use of immunotherapy approaches for a number of diseases and conditions is continuously gaining momentum. Included in this is the use of CD34+ stem cells from a patients’ own blood (autologously derived) to treat cardiovascular disease. CD34+ is derived from bone marrow and other tissue types. However, CD34+ stems cells are more widely known for their hematopoietic origin.
Studies have already shown that CD34+ stem cells can induce blood vessel growth in animal models of various cardiovascular conditions including ischemia (insufficient blood supply to an organ and related damage). There have also been clinical trials in humans to study the ability to use CD34+ stems cells to treat ischemic conditions in patients. This is important because there are a population of patients who do not respond to current treatment approaches to cardiovascular diseases.
CD34+ stem cells are multipotent and can self-renew. They can develop into blood and vessel cell types. The ability of CD34+ stem cells to reestablish vascular tissue has been studied in animals and humans for three major forms of ischemia (peripheral, myocardial, and cerebral). Studies in mice showed that CD34+ stem cells could help to recover blood flow to the ischemic limbs of diabetic mice.
A human clinical trial showed that CD34+ stem cells derived from bone marrow aspirate improved left ventricular ejection fraction (a measurement of heart failure) after intracoronary delivery. Clinical control trials also evaluate the utility of CD34+ stem cells to ameliorate cerebral ischemia caused by a number of conditions such as stroke. The new and emerging data will provide hope for alternative stem cell treatment strategies with the potential to curb cardiovascular disease mortality rates and improve patient quality of life.
HemaCare understand the importance of research into treatments for cardiovascular disease. Our CD34+ stem cells are customizable to meet your research needs. Call us today at 877-397-3087 for more information.
Reference: Mackie AR, Losordo DW. CD34-Positive Stem Cells in the Treatment of Heart and Vascular Disease in Human Beings. Texas Heart Institute Journal. 2011;38(5):474-485.